Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations
Matthias Egger,Romuald Bellmann,Robert Krause,Johannes Boyer,Daniela Jakšić,Martin Hoenigl
DOI: https://doi.org/10.2147/IDR.S372546
2023-04-13
Infection and Drug Resistance
Abstract:Matthias Egger, 1, 2 Romuald Bellmann, 3 Robert Krause, 1, 2 Johannes Boyer, 1 Daniela Jakši&cacute, 4 Martin Hoenigl 1, 2, 5, 6 1 Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria; 2 Biotechmed-Graz, Graz, Austria; 3 Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria; 4 Department of Microbiology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia; 5 Clinical and Translational Fungal-Working Group, University of California San Diego, San Diego, CA, USA; 6 Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria Correspondence: Martin Hoenigl, Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz, 8036, Austria, Tel +43 31638531425, Email Invasive mold diseases are devastating systemic infections which demand meticulous care in selection, dosing, and therapy monitoring of antifungal drugs. Various circumstances regarding PK/PD properties of the applied drug, resistance/tolerance of the causative pathogen or host intolerability can lead to failure of the initial antifungal therapy. This necessitates treatment adaption in the sense of switching antifungal drug class or potentially adding another drug for a combination therapy approach. In the current state of drastically limited options of antifungal drug classes adaption of therapy remains challenging. Current guidelines provide restricted recommendations only and emphasize individual approaches. However, novel antifungals, incorporating innovative mechanisms of action, show promising results in late stage clinical development. These will expand options for salvage therapy in the future potentially as monotherapy or in combination with conventional or other novel antifungals. We outline current recommendations for salvage therapy including PK/PD considerations as well as elucidate possible future treatment options for invasive aspergillosis and mucormycosis. Keywords: invasive fungal infections, aspergillosis, mucormycosis, salvage therapy Invasive mold infections (IMIs) remain associated with high morbidity and mortality. 1–4 Invasive aspergillosis (IA) and mucormycosis are the two most common IMIs in humans and, even when treated appropriately, associated with mortality rates of 30% and above. 5–10 Failure of first line treatment, which consists of antifungal treatment and often – especially in the case of mucormycosis – also of surgical debridement, 2,6,11 may occur due to (i) absence of clinical response resulting in refractory or breakthrough fungal infection, 12–14 (ii) intolerance/adverse events to first line antifungals, 15 or (iii) insufficient antifungal plasma levels 16–18 remaining below defined thresholds for clinical efficacy. 19–21 As a consequence, failure of first line antifungal treatment necessitating salvage treatment is quite common. Salvage therapy refers to the treatment of infected individuals who are refractory or intolerant to initial therapy administered for at least 7 days. General recommendations include a change in antifungal drug class. 22 However, the current reality of only three available drug classes, in association with intrinsic and acquired resistance complicating treatment of IMIs, renders this approach difficult to implement. Another challenge that we are currently facing is the lack of synergism between most of the available antifungals, 23 contributing to the uncertainties that surround the role of antifungal combination therapy (Table 1). Table 1 Antifungal Combination Therapy for Mucormycosis in Mice Nevertheless, hope is on the horizon, with a number of new antifungals, often the first compound of entirely new antifungal classes, currently in late stage clinical development. 24 These drugs may change the landscape of salvage therapy for both IA and mucormycosis. Here we review current salvage treatment recommendations, including their pharmacokinetic (PK) and pharmacodynamic (PD) properties, and give an outlook on how antifungal salvage treatment of IA and mucormycosis could present in the future. PK properties of agents utilized for salvage therapy of IA and mucormycosis are summarized in Table 2. Azole antifungals inhibit the fungal lanosterol 14-α-demethylase. As mold active azoles are generally strong CYP3A4 inhibitor numerous drug-drug interactions must be considered. 25,2 -Abstract Truncated-
pharmacology & pharmacy,infectious diseases